Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Join SI Premium – FREE
Piper Jaffray's Ian Somaiya issued a note Monday morning suggesting FDA approval of Bydureon increases chances for a takeover of Amylin (Nasdaq: AMLN).
Amylin shares are up almost 17 percent this afternoon following the news. The stock last traded at $14.20.
Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.
Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin.
Track all the market-moving analyst calls on shares of Amylin with our Analyst Ratings page.
Amylin shares are up almost 17 percent this afternoon following the news. The stock last traded at $14.20.
Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.
Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin.
Track all the market-moving analyst calls on shares of Amylin with our Analyst Ratings page.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Starts Vishay Intertechnology (VSH) at Buy
- Bernstein SocGen on DoorDash Inc. (DASH): 'What now for the stock?'
- BMO Capital: 'PG&E Corporation (PCG) Pulling Back but Standing By'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
